These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23721579)

  • 1. Identification of putative markers of triclabendazole resistance by a genome-wide analysis of genetically recombinant Fasciola hepatica.
    Hodgkinson J; Cwiklinski K; Beesley NJ; Paterson S; Williams DJ
    Parasitology; 2013 Oct; 140(12):1523-33. PubMed ID: 23721579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for high genetic diversity of NAD1 and COX1 mitochondrial haplotypes among triclabendazole resistant and susceptible populations and field isolates of Fasciola hepatica (liver fluke) in Australia.
    Elliott T; Muller A; Brockwell Y; Murphy N; Grillo V; Toet HM; Anderson G; Sangster N; Spithill TW
    Vet Parasitol; 2014 Feb; 200(1-2):90-6. PubMed ID: 24360656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.
    Elliott TP; Spithill TW
    Mol Biochem Parasitol; 2014 Nov; 198(1):45-7. PubMed ID: 25481750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica.
    Flanagan AM; Edgar HW; Forster F; Gordon A; Hanna RE; McCoy M; Brennan GP; Fairweather I
    Vet Parasitol; 2011 Feb; 176(1):34-42. PubMed ID: 21093156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal amplification of Fasciola hepatica in Galba truncatula: within and between isolate variation of triclabendazole-susceptible and -resistant clones.
    Hodgkinson JE; Cwiklinski K; Beesley N; Hartley C; Allen K; Williams DJL
    Parasit Vectors; 2018 Jun; 11(1):363. PubMed ID: 29941045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Threat of Triclabendazole Resistance in Fasciola hepatica.
    Kelley JM; Elliott TP; Beddoe T; Anderson G; Skuce P; Spithill TW
    Trends Parasitol; 2016 Jun; 32(6):458-469. PubMed ID: 27049013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single amino acid substitution in isozyme GST mu in Triclabendazole resistant Fasciola hepatica (Sligo strain) can substantially influence the manifestation of anthelmintic resistance.
    Fernández V; Estein S; Ortiz P; Luchessi P; Solana V; Solana H
    Exp Parasitol; 2015 Dec; 159():274-9. PubMed ID: 26542261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
    Ortiz P; Scarcella S; Cerna C; Rosales C; Cabrera M; Guzmán M; Lamenza P; Solana H
    Vet Parasitol; 2013 Jul; 195(1-2):118-21. PubMed ID: 23352107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasciola hepatica: histological demonstration of apoptosis in the reproductive organs of flukes of triclabendazole-sensitive and triclabendazole-resistant isolates, and in field-derived flukes from triclabendazole-treated hosts, using in situ hybridisation to visualise endonuclease-generated DNA strand breaks.
    Hanna RE; Forster FI; Brennan GP; Fairweather I
    Vet Parasitol; 2013 Jan; 191(3-4):240-51. PubMed ID: 23062689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica.
    McConville M; Brennan GP; Flanagan A; Edgar HW; Hanna RE; McCoy M; Gordon AW; Castillo R; Hernández-Campos A; Fairweather I
    Vet Parasitol; 2009 May; 162(1-2):75-88. PubMed ID: 19282108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
    Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
    Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole.
    Sanabria R; Ceballos L; Moreno L; Romero J; Lanusse C; Alvarez L
    Vet Parasitol; 2013 Mar; 193(1-3):105-10. PubMed ID: 23273779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of a novel panel of polymorphic microsatellite loci for the liver fluke, Fasciola hepatica, using a next generation sequencing approach.
    Cwiklinski K; Allen K; LaCourse J; Williams DJ; Paterson S; Hodgkinson JE
    Infect Genet Evol; 2015 Jun; 32():298-304. PubMed ID: 25796359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase of gluthatione S-transferase, carboxyl esterase and carbonyl reductase in Fasciola hepatica recovered from triclabendazole treated sheep.
    Scarcella S; Solana MV; Fernandez V; Lamenza P; Ceballos L; Solana H
    Mol Biochem Parasitol; 2013 Oct; 191(2):63-5. PubMed ID: 24041589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole.
    Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
    Vet Parasitol; 2012 Feb; 184(1):37-47. PubMed ID: 21872399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effects of triclabendazole (TCBZ) on the excretory-secretory products (ESP) of Fasciola spp parasites.
    Farahnak A; Golmohamdi T; Eshraghian M
    Acta Med Iran; 2012; 50(3):164-8. PubMed ID: 22418984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
    Alvarez LI; Solana HD; Mottier ML; Virkel GL; Fairweather I; Lanusse CE
    Parasitology; 2005 Oct; 131(Pt 4):501-10. PubMed ID: 16174415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasciola hepatica demonstrates high levels of genetic diversity, a lack of population structure and high gene flow: possible implications for drug resistance.
    Beesley NJ; Williams DJ; Paterson S; Hodgkinson J
    Int J Parasitol; 2017 Jan; 47(1):11-20. PubMed ID: 27940066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of vitellogenesis and spermatogenesis by triclabendazole (TCBZ) in a TCBZ-resistant isolate of Fasciola hepatica following incubation in vitro with a P-glycoprotein inhibitor.
    Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
    Parasitology; 2014 Jul; 141(8):1064-79. PubMed ID: 24889697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An amino acid substitution in Fasciola hepatica P-glycoprotein from triclabendazole-resistant and triclabendazole-susceptible populations.
    Wilkinson R; Law CJ; Hoey EM; Fairweather I; Brennan GP; Trudgett A
    Mol Biochem Parasitol; 2012 Nov; 186(1):69-72. PubMed ID: 22982092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.